Compare DCTH & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DCTH | EOLS |
|---|---|---|
| Founded | 1988 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 372.5M | 407.0M |
| IPO Year | 2015 | 2018 |
| Metric | DCTH | EOLS |
|---|---|---|
| Price | $12.59 | $6.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $22.00 | $15.50 |
| AVG Volume (30 Days) | 579.8K | ★ 763.1K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 107.53 | 1.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $297,176,000.00 |
| Revenue This Year | $24.54 | $13.27 |
| Revenue Next Year | $33.15 | $17.62 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 11.61 |
| 52 Week Low | $8.12 | $3.86 |
| 52 Week High | $13.44 | $10.20 |
| Indicator | DCTH | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 63.23 | 60.63 |
| Support Level | $10.26 | $6.44 |
| Resistance Level | N/A | $7.36 |
| Average True Range (ATR) | 0.57 | 0.30 |
| MACD | 0.12 | 0.01 |
| Stochastic Oscillator | 76.05 | 64.44 |
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.